Hyperuricemic PRP in Tendon Cells

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Andia, I ^a   Rubio Azpeitia, E ^a   Maffulli, N ^b,c  

^a BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^b UNIVERSITY OF SALERNO   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DECORIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA1; INTERLEUKIN DERIVATIVE; SCLEROPROTEIN; URIC ACID;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERURICEMIA; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; TENDON; THROMBOCYTE RICH PLASMA; UPREGULATION; ADULT; BIOSYNTHESIS; BLOOD; CELL PROLIFERATION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; MALE; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; CELL PROLIFERATION; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKINS; MALE; PLATELET-RICH PLASMA; REAL-TIME POLYMERASE CHAIN REACTION; TENDONS; URIC ACID;

EID: 84930987080     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/926481     Document Type: Article

References (28)

1. I. andia and N. Maffulli, "Platelet-rich plasma formuscle injury and tendinopathy," SportsMedicine and Arthroscopy Review, vol. 21, no. 4, pp. 191-198, 2013.
2. I. and ia, M. Sanchez, and N. Maffulli, "Tendon healing and platelet-rich plasma therapies," Expert Opinion on Biological Therapy, vol. 10, no. 10, pp. 1415-1426, 2010.
3. I. andia, P. M. Latorre, M. C. Gomez, N. Burgos-Alonso, M. Abate, and N.Maffulli, "Platelet-rich plasma in the conservative treatment of painful tendinopathy : A systematic review and meta-analysis of controlled studies," British Medical Bulletin, vol. 110, no. 1, pp. 99-115, 2014.
4. M. Abate, C. Schiavone, V. Salini, and I. and ia, "Occurrence of tendon pathologies in metabolic disorders," Rheumatology, vol. 52, no. 4, pp. 599-608, 2013.
5. J. C. Peerbooms, J. Sluimer, D. J. Bruijn, and T. Gosens, "Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind rand omized controlled trial: Platelet-rich plasma versus corticosteroid injection with a 1-year follow-up," The American Journal of Sports Medicine, vol. 38, no. 2, pp. 255-262, 2010.
6. S. Kesikburun, A. K. Tan, B. Yilmaz, E. Yas?ar, and K. Yazicioʇlu, "Platelet-rich plasma injections in the treatment of chronic rotator cuff tendinopathy: A rand omized controlled trial with 1-year follow-up,"The American Journal of Sports Medicine, vol. 41, no. 11, pp. 2609-2616, 2013.
7. F. Martinon, "Update on biology: Uric acid and the activation of immune and inflammatory cells," Current Rheumatology Reports, vol. 12, no. 2, pp. 135-141, 2010.
8. H. Uratsuji, Y. Tada, T. Kawashima et al., "P2Y 6 receptor signaling pathway mediates inflammatory responses induced by monosodium urate crystals," Journal of Immunology, vol. 188, no. 1, pp. 436-444, 2012.
9. K. M. Kim, G. N. Henderson, X. Ouyang et al., "A sensitive and specific liquid chromatography-tand emmass spectrometry method for the determination of intracellular and extracellular uric acid," Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 877, no. 22, pp. 2032-2038, 2009.
10. K. Lundgreen, O. B. Lian, L. Engebretsen, and A. Scott, "Tenocyte apoptosis in the torn rotator cuff: A primary or secondary pathological event? British Journal of Sports Medicine, vol. 45, no. 13, pp. 1035-1039, 2011.
11. Q. Lv, X.-F. Meng, F.-F. He et al., "High serum uric acid and increased risk of type 2 diabetes: A systemic review and metaanalysis of prospective cohort studies," PLoS One, vol. 8, no. 2, Article ID e56864, 2013.
12. F. Martinon, V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp, "Gout-associated uric acid crystals activate the NALP3 inflammasome," Nature, vol. 440, no. 7081, pp. 237-241, 2006.
13. K. Migita, T. Koga, K. Satomura et al., "Serum amyloid A triggers the mosodium urate -mediated mature interleukin-1β production from human synovial fibroblasts," Arthritis Research and Therapy, vol. 14, no. 3, article R119, 2012.
14. I. and ia and N. Maffulli, "Platelet-rich plasma for managing pain and inflammation in osteoarthritis," Nature Reviews Rheumatology, vol. 9, no. 12, pp. 721-730, 2013.
15. M. Kjaer, P. Magnusson, M. Krogsgaard et al., "Extracellular matrix adaptation of tendon and skeletal muscle to exercise," Journal of Anatomy, vol. 208, no. 4, pp. 445-450, 2006.
16. K. Legerlotz, G. C. Jones, H. R. C. Screen, and G. P. Riley, "Cyclic loading of tendon fascicles using a novel fatigue loading system increases interleukin-6 expression by tenocytes," Scandinavian Journal of Medicine and Science in Sports, vol. 23,no. 1, pp. 31-37, 2013.
17. J. I. Martin, J. Merino, L.M. Areizaga et al., "Platelet-richplasma (PRP) in chronic epicondylitis: Study protocol for a rand omized controlled trial," Trials, vol. 14, article 410, 2013.
18. M. L. Bayer, P. Schjerling, A. Herchenhan et al., "Release of tensile strain on engineered human tendon tissue disturbs cell adhesions, changes matrix architecture, and induces an inflammatory phenotype," PLoS ONE, vol. 9, no. 1, Article ID e86078, 2014.
19. L. Leone, M. Vetrano, D. Ranieri et al., "Extracorporeal shock wave treatment (ESWT) improves in vitro functional activities of ruptured human tendon-derived tenocytes," PLoS ONE, vol. 7, no. 11, Article ID e49759, 2012.
20. L. Yao, C. S. Bestwick, L. A. Bestwick, R. M. Aspden, and N. Maffulli, "Non-immortalized human tenocyte cultures as a vehicle for understand ing cellular aspects to tendinopathy," Translational medicine @ UniSa, vol. 1, pp. 173-194, 2011.
21. L. Yao, C. S. Bestwick, L. A. Bestwick, N. Maffulli, and R. M. Aspden, "Phenotypic drift in human tenocyte culture," Tissue Engineering, vol. 12, no. 7, pp. 1843-1849, 2006.
22. E. Anitua, I. andía,M. Sanchez et al., "Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture," Journal of Orthopaedic Research, vol. 23, no. 2, pp. 281-286, 2005.
23. E. Anitua, M. Sanchez, A. T. Nurden et al., "Autologous fibrin matrices: A potential source of biological mediators that modulate tendon cell activities," Journal of Biomedical Materials Research A, vol. 77, no. 2, pp. 285-293, 2006.
24. M. B. andersen, J. Pingel, M. Kjar, and H. Langberg, "Interleukin-6: A growth factor stimulating collagen synthesis in human tendon," Journal of Applied Physiology, vol. 110, no. 6, pp. 1549-1554, 2011.
25. T. Sillat, G. Barreto, P. Clarijs et al., "Toll-like receptors inhuman chondrocytes and osteoarthritic cartilage," Acta Orthopaedica, vol. 84, no. 6, pp. 585-592, 2013.
26. M. deMos, L. A. B. Joosten, B. Oppers-Walgreen et al., "Tendon degeneration is notmediated by regulation of toll-like receptors 2 and 4 in human tenocytes," Journal of Orthopaedic Research, vol. 27, no. 8, pp. 1043-1047, 2009.
27. A. Chhana, K. E. Callon, M. Dray et al., "Interactions between tenocytes and monosodium urate monohydrate crystals: Implications for tendon involvement in gout," Annals of the Rheumatic Diseases, vol. 73, no. 9, pp. 1737-1741, 2014.
28. I. andia and E. Rubio-Azpeitia, "Angiogenic and innate immune responses triggered by PRP in tendon cells are not modified by hyperuricemia," Muscles, Ligaments and Tendons Journal. In press.